Decoy Therapeutics (FP11) Stock Overview

Operates as a pre-clinical stage biotechnology company. More details

FP11 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

+ 3 more risks

FP11 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW497,995 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

497,995 investors already sharing narratives

View all narratives

Decoy Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Decoy Therapeutics
Historical stock prices
Current Share Price	US$5.23
52 Week High	US$75.12
52 Week Low	US$4.20
Beta	0.38
1 Month Change	0%
3 Month Change	-6.44%
1 Year Change	n/a
3 Year Change	-99.77%
5 Year Change	-99.90%
Change since IPO	-99.90%

Recent updates

Shareholder Returns

	FP11	DE Biotechs	DE Market
7D	0%	1.7%	4.1%
1Y	n/a	16.8%	2.9%

Return vs Industry: Insufficient data to determine how FP11 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how FP11 performed against the German Market.

Price Volatility

Is FP11's price volatile compared to industry and market?
FP11 volatility
FP11 Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.3%
Market Average Movement	5.6%
10% most volatile stocks in DE Market	12.5%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: FP11's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine FP11's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	11	Rick Pierce	decoytx.com

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company’s IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs.

Decoy Therapeutics Inc. Fundamentals Summary

How do Decoy Therapeutics's earnings and revenue compare to its market cap?
FP11 fundamental statistics
Market cap	€3.94m
Earnings (TTM)	-€11.20m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Is FP11 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FP11 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$13.03m
Earnings	-US$13.03m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-24.50
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did FP11 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/03 20:14
End of Day Share Price	2026/03/06 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Decoy Therapeutics Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Aydin Huseynov	Benchmark Company
Michael King	H.C. Wainwright & Co.
Kevin DeGeeter	Ladenburg Thalmann & Company

Decoy Therapeutics Inc.DB:FP11 Stock Report